Click here to navigate
- Contact sales for information
- Conditions of sale
- Related products
- Product inquiry
Features & Benefits
- All major HIV strains detectable with one strip: HIV-1, HIV-2, and HIV-1 group O
- Optimal specificity in screened-negative blood donors: 96.7% (290/300)
- High sensitivity in BBI panels
- Short and overnight procedures
- Color-coded reagents
- Ready-to-use reagents
- Four control lines to monitor 1) non-specific reactivity, 2) sample addition, 3) and 4) color development steps
- Fully automated strip processing possible using TENDIGO™, Auto-LIA™ 48, Auto-LiPA™ 48 or AutoBlot 3000(H)
- Objective, automated reading and interpretation of the strips possible using LiRAS® for Infectious Diseases
Antibodies to human immunodeficiency virus (HIV) have been detected in most patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC), and in many asymptomatic individuals belonging to high-risk groups. Enzyme-linked immunosorbent assays (ELISA) are widely used to screen human blood and plasma samples for the presence of these HIV antibodies.
However, since false-positive reactions have frequently been observed with current ELISA tests, it is strongly recommended to confirm repeatedly reactive samples by use of other reliable techniques (such as the INNO-LIA HIV I/II Score). Recombinant proteins and synthetic peptides from HIV-1 and HIV-2, and a synthetic peptide from HIV-1 group O, are coated as discrete lines on a nylon strip with plastic backing.
The INNO-LIA HIV I/II Score assay contains sequences derived from HIV-O sequences to allow the optimal detection of infections caused by this group of viruses. To allow the broad spectrum detection of all HIV infections, the INNO-LIA HIV I/II Score assay also contains separate lines for the differentiation of HIV-1 and HIV-2 infections.
This is important, as HIV-2 is less virulent, resulting in a better prognosis for the patient.
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
FAQHow does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).